KLEB-GAP - Klebsiella pneumoniae

The project will explore Klebsiella pneumoniae (Kp)-reservoirs using a first-in-kind One Health approach to develop new AMR diagnostics, innovative surveillance methods, and evaluate bacteriophages as treatment against multidrugresistant-Kp.

The KLEB-GAP project will provide new, timely insights into the ecology, antimicrobial resistance (AMR), and pathogenicity of Klebsiella pneumoniae (Kp), a WHO high-priority pathogen for research and development (R&D). Using a first-in-kind One Health detection and analysis approach, we will explore the presence, persistence, and transmission of Kp and related AMR within and across human, animal, and environmental reservoirs. The project will provide new, significant knowledge, and a foundation for (i) further development of global surveillance methodology to monitor the flow of Kp and related AMR across sectors, (ii) the development of new methods (whole metagenomic sequencing and targeted sequencing) beyond the state-of art for diagnostics and surveillance of Kp-clonal lineages involved in AMR dispersion and pathogenicity, and (iii) pre-clinical efficacy studies of bacteriophages as treatment of colonisation and infection by multidrug-resistant (MDR) Kp.

Project manager

Marianne Sunde


  • The Arctic University of Norway, Tromsø, Norway (UiT) (project owner)
  • Stavanger University Hospital, Stavanger, Norway (SUH)
  • University Hospital of North Norway, Tromsø, Norway (UNN)
  • Norwegian Veterinary Institute, Oslo, Norway (NVI)
  • Institute of Marine Research, Bergen, Norway (IMR)
  • Institut Pasteur, Paris, France (IP)
  • Karolinska Institutet, Stockholm, Sweden (KI)
  • Queen’s University of Belfast, Belfast, UK (QUB)
  • Monash University, Melbourne, Australia (Monash)
  • ACD Pharma, Oslo, Norway (ACD)
Research Areas
Antibiotic resistance, Bacteriology, Molecular biology